Pneumococcal 21-valent Conjugate Vaccine - Merck sharp & Dohme Corp
Alternative Names: CAPVAXIVE; Polyvalent pneumococcal conjugate vaccine - Merck Sharp & Dohme Corp; pPCV; V-116Latest Information Update: 13 Apr 2025
At a glance
- Originator Merck Sharp & Dohme Corp.
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Pneumococcal infections
Most Recent Events
- 26 Mar 2025 Registered for Pneumococcal infections (Prevention, In adults) in Norway, Liechtenstein, Iceland, European Union (IM)
- 26 Mar 2025 Immunogenicity and adverse events data from the phase III STRIDE-4 trial in Pneumococcal infections released by Merck
- 26 Mar 2025 Immunogenicity and adverse events data from the phase III STRIDE-5 trial in Pneumococcal infections released by Merck